7 In a survey involving 443 physicians, the reasons for discontinuing GLP-1 RAs were investigated in patients who had stopped treatment within the previous six months
Dosing frequency comparison The frequency differences are dramatic: Oral semaglutide tablets: Once daily Sublingual semaglutide drops: Once daily (potentially three times weekly at maintenance) Injectable semaglutide (Ozempic/Wegovy): Once weekly Injectable tirzepatide (Mounjaro/Zepbound): Once weekly Injectable liraglutide (Saxenda): Once daily The semaglutide vs tirzepatide comparison covers effectiveness differences between these two primary GLP-1 medications regardless of delivery method

In Conclusion Until there is more evidence-based research on the impact of GLC-1 receptor agonists on anesthesia, specifically conscious sedation, DOCS Education recommends a medical consult with the patients PCP or endocrinologist, and absent the strong recommendation to the contrary from their prescribing physician, have the patient withhold their weekly injectable GLP-1 receptor antagonist one week before sedation, and their daily GLP-1 receptor agonist on the day of the sedation appointment, and be NPO 6 hours before the appointment as usual
Most of the factors that promote osteoclastogenesis function in osteoclasts perform through enhancing RANKL expression on osteoblasts
Employer Strategies SmithRx Key Takeaways GLP-1 demand has exploded for diabetes/weight loss, creating shortages and huge pharmacy spending that can force employers to raise premiums or cut coverage